1. Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection
- Author
-
Dandekar, Satya, Dandekar, S ( Satya ), Abela, Irene A; https://orcid.org/0000-0002-5566-8628, Schwarzmüller, Magdalena; https://orcid.org/0000-0001-8384-2518, Ulyte, Agne; https://orcid.org/0000-0001-7419-9778, Radtke, Thomas; https://orcid.org/0000-0002-1723-1070, Haile, Sarah R; https://orcid.org/0000-0002-4704-6570, Ammann, Priska, Raineri, Alessia; https://orcid.org/0009-0007-7128-9656, Rueegg, Sonja, Epp, Selina, Berger, Christoph; https://orcid.org/0000-0002-2373-8804, Böni, Jürg; https://orcid.org/0000-0001-7925-4852, Manrique, Amapola; https://orcid.org/0000-0003-3982-398X, Audigé, Annette, Huber, Michael; https://orcid.org/0000-0002-0384-0000, Schreiber, Peter W; https://orcid.org/0000-0001-8123-2601, Scheier, Thomas; https://orcid.org/0000-0001-7805-1025, Fehr, Jan; https://orcid.org/0000-0003-1113-9895, Weber, Jacqueline, Rusert, Peter, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Puhan, Milo A; https://orcid.org/0000-0003-4721-1879, Kriemler, Susi; https://orcid.org/0000-0002-3384-7940, Trkola, Alexandra; https://orcid.org/0000-0003-1013-876X, Pasin, Chloé; https://orcid.org/0000-0001-8730-790X, Dandekar, Satya, Dandekar, S ( Satya ), Abela, Irene A; https://orcid.org/0000-0002-5566-8628, Schwarzmüller, Magdalena; https://orcid.org/0000-0001-8384-2518, Ulyte, Agne; https://orcid.org/0000-0001-7419-9778, Radtke, Thomas; https://orcid.org/0000-0002-1723-1070, Haile, Sarah R; https://orcid.org/0000-0002-4704-6570, Ammann, Priska, Raineri, Alessia; https://orcid.org/0009-0007-7128-9656, Rueegg, Sonja, Epp, Selina, Berger, Christoph; https://orcid.org/0000-0002-2373-8804, Böni, Jürg; https://orcid.org/0000-0001-7925-4852, Manrique, Amapola; https://orcid.org/0000-0003-3982-398X, Audigé, Annette, Huber, Michael; https://orcid.org/0000-0002-0384-0000, Schreiber, Peter W; https://orcid.org/0000-0001-8123-2601, Scheier, Thomas; https://orcid.org/0000-0001-7805-1025, Fehr, Jan; https://orcid.org/0000-0003-1113-9895, Weber, Jacqueline, Rusert, Peter, Günthard, Huldrych F; https://orcid.org/0000-0002-1142-6723, Kouyos, Roger D; https://orcid.org/0000-0002-9220-8348, Puhan, Milo A; https://orcid.org/0000-0003-4721-1879, Kriemler, Susi; https://orcid.org/0000-0002-3384-7940, Trkola, Alexandra; https://orcid.org/0000-0003-1013-876X, and Pasin, Chloé; https://orcid.org/0000-0001-8730-790X
- Abstract
Knowledge of the interplay between human coronavirus (HCoV) immunity and severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection is critical to understanding the coexistence of current endemic coronaviruses and to building knowledge potential future zoonotic coronavirus transmissions. This study, which retrospectively analyzed a large cohort of individuals first exposed to SARS-CoV-2 in Switzerland in 2020–2021, revealed several key findings. Pre-existing HCoV immunity, particularly mucosal antibody responses, played a significant role in improving SARS-CoV-2 immune response upon infection and reducing symptoms development. Mucosal neutralizing activity against SARS-CoV-2, although low in magnitude, retained activity against SARS-CoV-2 variants underlining the importance of maintaining local mucosal immunity to SARS-CoV-2. While the cross-protective effect of HCoV immunity was not sufficient to block infection by SARS-CoV-2, the present study revealed a remarkable impact on limiting symptomatic disease. These findings support the feasibility of generating pan-protective coronavirus vaccines by inducing potent mucosal immune responses.
- Published
- 2024